A Randomized, Prospective, Double-Blind, Comparative Placebo-Controlled Study of Intravenous Iron Isomaltoside 1000 (Monofer®) Administered by Infusions to Iron-Deficient Blood Donors
Phase of Trial: Phase III
Latest Information Update: 19 Mar 2018
Price : $35 *
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Pharmacosmos
- 31 Aug 2018 Biomarkers information updated
- 14 Mar 2018 Status changed from recruiting to completed.
- 01 Mar 2016 Planned End Date changed from 1 Sep 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.